8. Natalizumab de-escalation to interferon beta-1b in multiple sclerosis patients

Zecca, Chiara; Meier, Dominik; Candrian, Ursula; Cotton, François; Nadarajah, N.; Sintzel, Martina; Gobbi, Claudio

doi:10.1016/j.clinph.2012.03.072

Search citation statements

Order By: Relevance

Paper Sections

Select...

Considerations For Stopping Natalizumab1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2013

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early results indicated some nonsignificant recurrence of clinical activity and increased new T2 lesion load on the β-interferon arm. [53]. It can be seen, therefore, that the data to fully inform this difficult decision are not currently available.…”

Section: Considerations For Stopping Natalizumabmentioning

confidence: 99%

Natalizumab Therapy for Multiple Sclerosis

Chataway

Miller

2013

Neurotherapeutics

View full text Add to dashboard Cite

The treatment of relapsing remitting multiple sclerosis has witnessed major progress since the first effective disease modifying treatment, ß-interferon, became available in 1993. One of the most remarkable new treatments has been natalizumab. This review describes the evolution of this humanized anti-α4ß1 monoclonal antibody, from preclinical experimental research through proof-of-concept (phase 1/2) and pivotal (phase 3) clinical trials to the now extensive experience of its use in clinical practice. The future potential and challenges of natalizumab and oral therapies with a similar mechanism of action are also discussed.

show abstract

Section: Considerations For Stopping Natalizumabmentioning

confidence: 99%

Natalizumab Therapy for Multiple Sclerosis

Chataway

Miller

2013

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

Switching Therapies in Multiple Sclerosis

Coyle

2013

CNS Drugs

View full text Add to dashboard Cite

There are currently nine approved disease modifying therapies for relapsing forms of multiple sclerosis, with six distinct mechanisms of action. All have side effects, and none are cures. When a patient cannot tolerate therapy, or there is unacceptable breakthrough disease activity, the most common approach is to change drug. No universal guidelines exist for switching therapy. This overview will propose switch principles and suggestions.

show abstract

8. Natalizumab de-escalation to interferon beta-1b in multiple sclerosis patients

Cited by 2 publications

References 0 publications

Natalizumab Therapy for Multiple Sclerosis

Natalizumab Therapy for Multiple Sclerosis

Switching Therapies in Multiple Sclerosis

Contact Info

Product

Resources

About